Clinical Trials Browser

Phase 2 × Renal Insufficiency × Clear all

NCT06004661 2026-03-06

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Phase 2 Recruiting

Renal Insufficiency

NCT07029503 2026-02-24

SCARF-1

Phase 2 Recruiting

Heart Failure, Lymphoma, Follicular, Renal Insufficiency, Chronic, Renal Insufficiency

NCT04240054 2026-01-28

VICD

Phase 2 Recruiting

Multiple Myeloma, Renal Insufficiency

NCT03101995 2025-05-28

Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease

Phase 2 Recruiting

Uterine Cervical Neoplasms, Renal Insufficiency

NCT04352205 2024-07-01

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Phase 2 Terminated

Multiple Myeloma, Renal Insufficiency

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Phase 2 Unknown

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Phase 2 Unknown

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02424851 2022-01-27

OPTIMAL

Phase 2 Completed

31 enrolled 13 charts

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02045017 2021-08-27

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Phase 2 Completed

Multiple Myeloma, Renal Insufficiency

NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

16 enrolled 11 charts

Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

NCT01270932 2017-12-29

Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients

Phase 2 Completed

Multiple Myeloma, Renal Insufficiency

NCT00721734 2017-05-02

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Phase 2 Completed

50 enrolled 33 charts

Multiple Myeloma, Renal Insufficiency, Neoplasms, Plasma Cell

NCT00779922 2016-10-11

Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

Phase 2 Completed

Multiple Myeloma, Renal Insufficiency

NCT01599013 2015-12-08

JASINT1

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urogenital Neoplasms, Urologic Neoplasms, Renal Insufficiency

NCT01084837 2015-09-17

RENVEL

Phase 2 Completed

Multiple Myeloma, Renal Insufficiency

NCT00401804 2013-01-24

Bortezomib-Dexamethasone-Doxorubicin-Study

Phase 2 Completed

Multiple Myeloma, Renal Insufficiency